VWM
FATE icon

Vigilare Wealth Management’s Fate Therapeutics FATE Stock Holding History

Vigilare Wealth Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,800
Closed -$243K – 201
2021
Q2 		$243K Buy
+2,800
New +$226K 0.15% 175
2021
Q1 		– Sell
-2,395
Closed -$218K – 201
2020
Q4 		$218K Sell
2,395
-3,555
-60% -$221K 0.21% 122
2020
Q3 		$238K Sell
5,950
-730
-11% -$25.5K 0.25% 98
2020
Q2 		$229K Buy
+6,680
New +$199K 0.23% 97

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vigilare Wealth Management's FATE Position: Q3 2021 in Review

Vigilare Wealth Management sold out of Fate Therapeutics (FATE) in Q3 2021, closing a stake of 2,800 shares — an estimated $243K sold.

Vigilare Wealth Management first reported a position in FATE in Q2 2020 and held it in 4 quarters. The position peaked at $243K in Q2 2021. 265 funds tracked by Wall St. Rank hold FATE as of Q3 2021.

  • Vigilare Wealth Management reported no remaining Fate Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Vigilare Wealth Management sold 2,800 Fate Therapeutics shares in Q3 2021, an estimated $243K.
  • Vigilare Wealth Management first reported a position in Fate Therapeutics in Q2 2020 and held it in 4 quarters.
  • Vigilare Wealth Management's Fate Therapeutics position peaked at $243K in Q2 2021.
  • 265 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2021.

Based on Vigilare Wealth Management's 13F filing for Q3 2021, filed 19 Oct 2021.